Aldeyra The

NASDAQ: ALDX · Healthcare · Biotechnology

PublicHQ Lexington, MA · MiddlesexCIK 0001341235Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 43DQ —GM —SS 47

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$33.8M

Employees

as of 2026-08-14

Market cap

$86.9M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$33.8M-$33.8M2025

Operating income-$35.3M-$35.3M2025

Total assets$72.1M$72.1M2025

Liabilities$27.8M$27.8M2025

Equity$44.3M$44.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Aldeyra The’s financial profile?

Aldeyra The earned -$33.8M in FY2025 net income.

Peers · Healthcare

Cognition Therapeutics, Inc.——Acrivon Therapeutics, Inc. Common Stock——NDT Pharmaceuticals Inc.——Oncolytics Biotech Inc.——Adicet Bio, Inc.——Dogwood Therapeutics, Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOTodd C. Brady

SectorHealthcare

IndustryBiotechnology

HeadquartersLexington, MA

ExchangeNASDAQ: ALDX

Employees7

IPO date2014-05-02

Latest filings

10-Q2026-08-06 8-K2026-07-30 8-K2026-07-15 8-K2026-06-10 10-Q2026-05-07 8-K2026-05-01 DEF 14A2026-04-27 8-K2026-04-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.